Alexion

scrapheap
Biotech

AZ licenses discarded rare disease drug to Monopar Therapeutics

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline, licensing Wilson disease candidate ALXN-1840.
Kevin Dunleavy Oct 24, 2024 2:54pm
Illustration connected puzzle pieces with the acronym MA

AstraZeneca inks $800M buyout to snag phase 3 rare disease drug

Mar 14, 2024 9:47am
spring slinky competition overtake crush absorb

SpringWorks eyes AstraZeneca's Koselugo market with phase 2 data

Nov 16, 2023 10:59am
Graphic of a spaceship landing on Mars surface

Voyager asset lands on planet Alexion after Pfizer handoff

Nov 6, 2023 4:01pm
Photo of a ballerina striking a pose at the center of the stage while the crowd watches

Novartis’ iptacopan has ‘faultless’ performance in phase 3

Oct 2, 2023 11:09am
merge MA railway train tracks path together

AstraZeneca converges with Verge's AI tech in $42M R&D pact

Sep 8, 2023 7:00am